{"id":"W2147881986","doi":"10.1186/1756-8722-5-67","title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Takeda Oncology; European Society for Medical Oncology; National Comprehensive Cancer Network","keywords":"Rituximab; Medicine; Bortezomib; Internal medicine; Follicular lymphoma; International Prognostic Index; Hazard ratio; Lymphoma; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Confidence interval; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005537706,0.002068701,0.005645607,0.0006368433,0.0004415044,0.001671856,0.001096602,0.00163129,0.003651049],"category_scores_gemma":[0.005993179,0.0006764615,0.00929414,0.0007723604,0.0007299306,0.0009553605,0.0006824457,0.001980411,0.0004398167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001289548,"about_ca_system_score_gemma":0.001455969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001224478,"about_ca_topic_score_gemma":0.002915937,"domain_scores_codex":[0.9968935,0.00198344,0.0003793284,0.0003519585,0.0001409218,0.0002508012],"domain_scores_gemma":[0.9975778,0.00100536,0.0006787514,0.0002908006,0.0001331308,0.0003141079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.969495,0.0006129061,0.002517711,0.0009280586,0.0180722,0.00006286401,0.0000509455,0.0004429155,0.0008416308,0.0000596384,0.0003921432,0.006524004],"study_design_scores_gemma":[0.949195,0.02243106,0.007057484,0.0001422302,0.01847646,0.00008469667,0.00007098341,0.001119396,0.000278861,0.0005422927,0.0005678218,0.00003360904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9600658,0.03050959,0.001391537,0.0009830251,0.000856637,0.003360804,0.001235443,0.0001363048,0.001460805],"genre_scores_gemma":[0.9908931,0.003011385,0.0008318337,0.0008420293,0.0003675147,0.002532085,0.000833646,0.00002337066,0.0006650568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005645607,"threshold_uncertainty_score":0.0292865,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01518842291036072,"score_gpt":0.3100544583008139,"score_spread":0.2948660353904531,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}